title: Is there an end in sight for encapsulating peritoneal sclerosis?
authors.affiliation: Royal London Hospital - Nephrology, London, United Kingdom Royal London Hospital - Renal Unit, Whitechapel, London, United Kingdom.
authors.forename: Klara
authors.initials: K
authors.lastname: Paudel
authors.affiliation: Royal London Hospital - Nephrology, London, United Kingdom Royal London Hospital - Renal Unit, Whitechapel, London, United Kingdom s.fan@qmul.ac.uk stanley.fan@virgin.net.
authors.forename: Stanley L
authors.initials: SL
authors.lastname: Fan
mesh_terms: D006801:Humans; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects* / Q000379:methods; D056627:Peritoneal Fibrosis / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy; D011322:Primary Prevention / Q000379:methods*; D011379:Prognosis; D006435:Renal Dialysis / Q000379:methods; D018570:Risk Assessment; D012720:Severity of Illness Index; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D013629:Tamoxifen